Pediatric Neuroblastoma Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The market is segmented by Treatment Type (Chemotherapy, Surgery, Retinoid therapy, Others), by Risk Group, and by Geography.

Market Snapshot

pediatric neuro
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 6.3 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The pediatric neuroblastoma treatment market studied was projected to grow with a CAGR of nearly 6.3% over the forecast period. The major factor attributing to the growth of the market is the increasing prevalence of neuroblastoma in the pediatric population. According to the National Cancer Institute, the prevalence is about 1 case per 7,000 live births, the incidence is about 10.54 cases per 1 million per year in children younger than 15 years in the United States every year. Nearly 37% of patients are diagnosed are infants, and 90% are younger than 5 years at diagnosis. Furthermore, the growing investments in research and development programs by the government to develop the medical infrastructure in the pediatric section and increasing awareness of the treatment of pediatric neuroblastoma is boosting the market growth. However, the high cost involved in pediatric neuroblastoma treatment is a major drawback of market growth.

Scope of the Report

As per the scope of the report neuroblastoma is cancer that develops from immature nerve cells found in several areas of the body, most commonly arises in and around the adrenal glands. Neuroblastoma is the most common extracranial solid tumor in childhood. 

By Treatment Type
Chemotherpay
Immunotherapy
Others
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Chemotherapy Segment is Dominating the Pediatric Neuroblastoma Treatment Market.

  • Chemotherapy uses anti-cancer drugs, which are usually delivered into a vein. The drugs enter the bloodstream and travel throughout the body to reach and destroy cancer cells. This makes chemo useful for treating neuroblastoma that has spread to the lymph nodes, bone marrow, liver, lungs, or other organs.
  • The increasing growth rate of the segment is mainly attributed to the effectiveness of chemotherapy drugs in neuroblastoma treatment along with the increasing incidence of the disease in pediatric population. Moreover, chemotherapy is the treatment of choice to slow down disease progression and reduce symptoms. It is also combined with other treatments such as radiation therapy or surgery for more effective results.
  • Whether if a child with neuroblastoma will undergo chemotherapy varies on their risk group. Some children with neuroblastoma are treated with chemo either before surgery or after surgery. In few other cases, especially when the cancer has spread too far to be removed completely by surgery, chemotherapy is the main treatment.
  • Morover, low survival rates and growing burden among the pediatrics are projected to boost the overall market growth.
neuro.png

North America Dominates the Market and Expected to do Same in the Forecast Period.

North America is expected to dominate the overall market, throughout the forecast period. The market growth is due to factors such as the high prevalence of pediatric neuroblastoma in the region, established healthcare infrastructure are some of the key factors accountable for its large share in the market. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase market growth. In this region the United States has the maximum share due to supportive healthcare policies, a high number of patients, and a developed healthcare market. According to the American Cancer Society’s Cancer Statistics, nearly 800 new cases of neuroblastoma are reported in the United States every year. The above statistics prove that the high prevalence of the disease is boosting the market in the region.

Pediatric Neuroblastoma Market - Growth Rate by Region - Image

Competitive Landscape

The pediatric neuroblastoma treatment market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are United Therapeutics Corporation, APEIRON Biologics AG, Baxter, CELLECTAR BIOSCIENCES, INC, Sun Pharmaceutical Industries, Inc., Pfizer, Inc., Bayer AG, MacroGenics, Inc., Sartorius AG.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Burden Of Pediatric Neuroblastoma Coupled With Increasing R&D

      2. 4.2.2 Rise in Awareness of Available Treatment For Cancer

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost And Side Effects Associated With Cancer Therapy

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Treatment Type

      1. 5.1.1 Chemotherpay

      2. 5.1.2 Immunotherapy

      3. 5.1.3 Others

    2. 5.2 Distribution Channel

      1. 5.2.1 Hospital Pharmacies

      2. 5.2.2 Retail Pharmacies

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 United Therapeutics Corporation

      2. 6.1.2 APEIRON Biologics AG

      3. 6.1.3 Baxter

      4. 6.1.4 APAC Biotech

      5. 6.1.5 Sun Pharmaceutical Industries, Inc.

      6. 6.1.6 Pfizer, Inc.

      7. 6.1.7 Bayer AG

      8. 6.1.8 MacroGenics, Inc.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Pediatric Neuroblastoma Treatment Market market is studied from 2018 - 2026.

The Pediatric Neuroblastoma Treatment Market is growing at a CAGR of 6.3% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

United Therapeutics Corporation, APEIRON Biologics AG, Baxter International, APAC Biotech, Sun Pharmaceutical Industries, Inc. are the major companies operating in Pediatric Neuroblastoma Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!